3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neuroblastoma
2
Lymphoma
2
Skin Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metabolic Diseases
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunologic Deficiency Syndromes
1
Hepatoblastoma
1
Ganglioneuroblastoma
1
Anemia, Aplastic
1
Interventions
Cyclophosphamide
21
venetoclax
18
pembrolizumab
16
Dexamethasone
16
fludarabine
14
Cytarabine
13
Gemcitabine
9
pomalidomide
8
Rituximab
8
Carboplatin
8
Azacitidine
8
glofitamab
7
fludarabine phosphate
7
Lenalidomide
7
Immunotherapy, Adoptive
7
selinexor
6
Paclitaxel
6
Injections
6
Granulocyte Colony-Stimulating Factor
6
Cisplatin
6
daratumumab
5
Temozolomide
5
Oxaliplatin
5
Bevacizumab
5
zanubrutinib
4
ruxolitinib
4
Surgical Procedures, Operative
4
Nivolumab
4
Drug Therapy
4
Decitabine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Recurrence
×
Influenza Vaccines
×
Clear all
NCT07502287
2026-03-30
DUAL-NK-NB
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled